IRWD

#2718
Ironwood Pharmaceuticals, Inc. - Class A Common Stock
3.7 5 USD
-0.02%
Market Price
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
3.74
3.85
Year Range
1.41
5.78
Daily Change
-1.83%
Monthly Change
-8.54%
6 month change
+4.75%
Year Change
+128.66%
Previous Close
3.8 2
Open
3.8 2
Low
3.7 4
High
3.8 5
Open full chart

Financials

Overview Statement Statistics Documents
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
22.47
Price to sales ratio
1.85

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
2329
HROW
Harrow, Inc. - Common Stock
29.12 USD-0.82%-4.77%-15.59%-25.33%1.09 B USD
2611
COLL
Collegium Pharmaceutical, Inc. - Common Stock
22.06 USD-0.14%+0.87%-3.25%-37.22%718.18 M USD
2733
AQST
Aquestive Therapeutics, Inc. - Common Stock
4.82 USD+0.84%+5.47%+2.55%-26.86%604.97 M USD
2834
EOLS
Evolus, Inc. - Common Stock
7.75 USD+0.26%+3.75%-1.90%+26.02%511.89 M USD

Frequently asked questions about Ironwood Pharmaceuticals, Inc. - Class A

What is the Ironwood Pharmaceuticals, Inc. - Class A stock price today?

The current price of Ironwood Pharmaceuticals, Inc. - Class A (IRWD) is 3.75. Over the past 24 hours, the stock has changed by -1.83%. Follow the IRWD chart for real-time price dynamics.

What is the stock ticker of Ironwood Pharmaceuticals, Inc. - Class A?

Ironwood Pharmaceuticals, Inc. - Class A trades under the ticker IRWD. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Ironwood Pharmaceuticals, Inc. - Class A stock going up?

IRWD has changed by +2.74% over the last week, -8.54% over the last month, and +128.66% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Ironwood Pharmaceuticals, Inc. - Class A?

Ironwood Pharmaceuticals, Inc. - Class A currently has a market capitalization of 619.65 M. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What were Ironwood Pharmaceuticals, Inc. - Class A earnings last quarter?

Last quarter, Ironwood Pharmaceuticals, Inc. - Class A reported earnings of 0.31 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was Ironwood Pharmaceuticals, Inc. - Class A revenue for the last quarter?

Ironwood Pharmaceuticals, Inc. - Class A reported quarterly revenue of 113.04 M. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was Ironwood Pharmaceuticals, Inc. - Class A net income for the last quarter?

Ironwood Pharmaceuticals, Inc. - Class A reported net income of 51.29 M for the last quarter. The previous quarter showed 40.77 M, which means net income changed by +25.80%.

How many employees does Ironwood Pharmaceuticals, Inc. - Class A have?

As of the latest available data, Ironwood Pharmaceuticals, Inc. - Class A has 100 employees. Workforce size can provide additional context about the company's scale and operations.

What is Ironwood Pharmaceuticals, Inc. - Class A EBITDA?

Ironwood Pharmaceuticals, Inc. - Class A EBITDA is 79.76 M, and its EBITDA margin is 70.56%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Ironwood Pharmaceuticals, Inc. - Class A stock?

You can buy Ironwood Pharmaceuticals, Inc. - Class A (IRWD) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Ironwood Pharmaceuticals, Inc. - Class A stock?

Investing in Ironwood Pharmaceuticals, Inc. - Class A requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the IRWD chart and related analysis on metatrader.com as part of your research.

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc. Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery. In 2002 the company hired John Talley to lead their antifungal drug discovery efforts, which at the time were focused on identifying small molecules that could inhibit fungal invasins, along with Mark Currie who had also worked at Searle division of Monsanto with Talley, and then had gone to Sepracor, and also Richard Bailey, who had run Monsanto's nutritional business. Currie directed the efforts that led to the discovery of linaclotide, which was based on an enterotoxin produced by some strains of Escherichia coli that cause traveler's diarrhea. By 2004 the company had raised $99M and was preparing a Phase I trial for linaclotide.

News